Zobrazeno 1 - 10
of 311
pro vyhledávání: '"Marañón, J."'
Autor:
Núñez-Álvarez Y; Institut de Génétique Humaine, Université de Montpellier, CNRS UMR9002, Montpellier, France., Espie-Caullet T; Institut de Génétique Humaine, Université de Montpellier, CNRS UMR9002, Montpellier, France.; Institut Curie, Paris-Saclay Research University, CNRS UMR3348, 91401 Orsay, France.; Team supported by la Ligue contre le Cancer, France., Buhagiar G; Institut Curie, Paris-Saclay Research University, CNRS UMR3348, 91401 Orsay, France.; Team supported by la Ligue contre le Cancer, France., Rubio-Zulaika A; Department of Neurosciences, Biogipuzkoa Health Research Institute, 20014 San Sebastián, Spain., Alonso-Marañón J; Department of Neurosciences, Biogipuzkoa Health Research Institute, 20014 San Sebastián, Spain., Luna-Pérez E; Institut Curie, Paris-Saclay Research University, CNRS UMR3348, 91401 Orsay, France.; Team supported by la Ligue contre le Cancer, France., Blazquez L; Department of Neurosciences, Biogipuzkoa Health Research Institute, 20014 San Sebastián, Spain.; Ikerbasque, Basque Foundation for Science, 48009 Bilbao, Spain.; CIBERNED, ISCIII (CIBER, Carlos III Institute, Spanish Ministry of Sciences and Innovation), 28031 Madrid, Spain., Luco RF; Institut de Génétique Humaine, Université de Montpellier, CNRS UMR9002, Montpellier, France.; Institut Curie, Paris-Saclay Research University, CNRS UMR3348, 91401 Orsay, France.; Team supported by la Ligue contre le Cancer, France.
Publikováno v:
Nucleic acids research [Nucleic Acids Res] 2024 Oct 28; Vol. 52 (19), pp. 11926-11939.
IκB kinase-α coordinates BRD4 and JAK/STAT signaling to subvert DNA damage-based anticancer therapy.
Autor:
Pecharromán I; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain., Solé L; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain., Álvarez-Villanueva D; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain., Lobo-Jarne T; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain., Alonso-Marañón J; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain., Bertran J; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.; Faculty of Science and Technology, University of Vic - Central University of Catalonia, Vic, Spain., Guillén Y; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain., Montoto Á; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain., Martínez-Iniesta M; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain., García-Hernández V; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain., Giménez G; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain., Salazar R; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain., Santos C; Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL)-CIBERONC, L'Hospitalet de Llobregat, Barcelona, Spain., Garrido M; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain., Borràs E; Proteomics Unit, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain., Sabidó E; Proteomics Unit, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.; Proteomics Unit, Universitat Pompeu Fabra, Barcelona, Spain., Bonfill-Teixidor E; Vall d'Hebron Institute of Oncology (VHIO), CIBERONC, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain., Iurlaro R; Vall d'Hebron Institute of Oncology (VHIO), CIBERONC, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain., Seoane J; Vall d'Hebron Institute of Oncology (VHIO), CIBERONC, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain., Villanueva A; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.; Xenopat S.L., Parc Cientific de Barcelona (PCB), Barcelona, Spain., Iglesias M; Department of Pathology, Institut Mar d'Investigacions Mèdiques, CIBERONC, Universitat Autònoma de Barcelona, Barcelona, Spain., Bigas A; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.; Josep Carreras Leukemia Research Institute, Badalona, Spain., Espinosa L; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, Spain.
Publikováno v:
The EMBO journal [EMBO J] 2023 Nov 02; Vol. 42 (21), pp. e114719. Date of Electronic Publication: 2023 Sep 22.
Autor:
Marañón Di Leo, J., Marañón, J.
Publikováno v:
In Journal of Molecular Structure: THEOCHEM 2005 729(1):53-57
Autor:
Di Leo, J. Marañón, Marañón, J.
Publikováno v:
In Chemical Physics Letters 2005 404(4):257-262
Autor:
Di Leo, J. Marañón *, Marañón, J.
Publikováno v:
In Journal of Molecular Structure: THEOCHEM 2004 709(1):163-166
Autor:
Di Leo, J.Marañon, Marañon, J ∗
Publikováno v:
In Journal of Molecular Structure: THEOCHEM 2004 672(1):221-229
Autor:
Marañón Di Leo, J, Marañón, J ∗
Publikováno v:
In Journal of Molecular Structure: THEOCHEM 2003 623(1):159-166
Autor:
Solé L; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain., Lobo-Jarne T; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain., Álvarez-Villanueva D; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain., Alonso-Marañón J; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain., Guillén Y; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain., Guix M; Department of Oncology, Institut Mar d'Investigacions Mèdiques, CIBERONC, Universitat Pompeu Fabra, Barcelona, 08003, Spain., Sangrador I; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain., Rozalén C; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain., Vert A; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain., Barbachano A; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.; Department of Cancer Biology, Instituto de Investigaciones Biomédicas 'Alberto Sols', Spanish National Research Council (CSIC)-Autonomous University of Madrid (UAM) and IdiPAZ, Madrid, Spain., Lop J; Department of Pathology, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona, Barcelona, 08003, Spain., Salido M; Department of Pathology, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona, Barcelona, 08003, Spain., Bellosillo B; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.; Department of Pathology, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona, Barcelona, 08003, Spain., García-Romero R; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain., Garrido M; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain., González J; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain., Martínez-Iniesta M; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain., López-Arribillaga E; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain.; Group of Biomedical Genomics, Institut de Recerca Biomedica (IRB), Barcelona, 08028, Spain., Salazar R; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain., Montagut C; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.; Department of Oncology, Institut Mar d'Investigacions Mèdiques, CIBERONC, Universitat Pompeu Fabra, Barcelona, 08003, Spain., Torres F; Biostatistics Unit, Medical School, Universitat Autònoma de Barcelona, Barcelona, Spain., Iglesias M; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.; Department of Pathology, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona, Barcelona, 08003, Spain., Celià-Terrassa T; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain., Muñoz A; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain.; Department of Cancer Biology, Instituto de Investigaciones Biomédicas 'Alberto Sols', Spanish National Research Council (CSIC)-Autonomous University of Madrid (UAM) and IdiPAZ, Madrid, Spain., Villanueva A; Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain., Bigas A; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain. abigas@imim.es.; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. abigas@imim.es., Espinosa L; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Barcelona, 08003, Spain. lespinosa@imim.es.; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain. lespinosa@imim.es.
Publikováno v:
Nature communications [Nat Commun] 2022 May 23; Vol. 13 (1), pp. 2866. Date of Electronic Publication: 2022 May 23.
Autor:
Cantero-Recasens G; Renal Physiopathology Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain., Alonso-Marañón J; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC Hospital del Mar, Barcelona, Spain., Lobo-Jarne T; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC Hospital del Mar, Barcelona, Spain., Garrido M; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC Hospital del Mar, Barcelona, Spain., Iglesias M; Department of Pathology, Institut Mar d'Investigacions Mèdiques, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Espinosa L; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC Hospital del Mar, Barcelona, Spain., Malhotra V; Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology, Barcelona, Spain.; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
Publikováno v:
ELife [Elife] 2022 Feb 08; Vol. 11. Date of Electronic Publication: 2022 Feb 08.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.